Blueprint Medicines Corp
BPMC127.960USD
-0.250-0.20%
收盤 06/13, 16:00（美東）報價延遲15分鐘
8.26B總市值
虧損本益比TTM
關於 Blueprint Medicines Corp 公司
Blueprint Medicines Corporation 是一家全球精準治療公司，正在過敏/炎症和腫瘤/血液學兩個領域發明改變生命的藥物。該公司向美國和歐洲的患者提供其獲批的藥物，包括 AYVAKIT/AYVAKYT (avapritinib) 和 GAVRETO (pralsetinib)，並在全球範圍內推進針對系統性肥大細胞增多症 (SM)、肺癌、乳腺癌和其他基因組定義的癌症以及癌症免疫療法的多個項目。該公司的產品線還包括 Elenestinib (BLU-263) (KIT)、AYVAKIT (avapritinib) (KIT)、野生型 KIT 研究項目、GAVRETO (pralsetinib) (RET)、BLU-945 (EGFR)、BLU-525 (EGFR)、BLU-451 (EGFR 外顯子 20 插入)、BLU-222 (CDK2)、AYVAKIT (PDGFRA)、GAVRETO (RET)、BLU-222 (CDK2) 和 BLU-852 (MAP4K1)。該公司正在開發一種口服、有效且高選擇性的試驗性 KIT 抑制劑 Elenestinib (BLU-263)，用於治療惰性 SM 和其他肥大細胞疾病。
公司簡介
公司代碼BPMC
公司名稱Blueprint Medicines Corp
上市日期Apr 30, 2015
成立日期2008
CEOMs. Kathryn D (Kate) Haviland
員工數量649
證券類型Ordinary Share
年結日Apr 30
公司地址45 Sidney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02139
電話16173747580
網址https://www.blueprintmedicines.com/
公司代碼BPMC
上市日期Apr 30, 2015
成立日期2008
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
--
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
Lead Independent Director
Lead Independent Director
11.01K
+3.36%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
--
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
收入明細
單位: USD更新時間: 4月6日 週日
單位: USD更新時間: 4月6日 週日
FY2024Q3
FY2024Q2
FY2024Q1
業務USD
名稱
營收
佔比
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
地區USD
名稱
營收
佔比
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
業務
地區
業務USD
名稱
營收
佔比
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
10.25%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.57%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Other
63.20%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
10.25%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.57%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Other
63.20%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
50.24%
Investment Advisor
44.17%
Hedge Fund
8.89%
Research Firm
2.98%
Sovereign Wealth Fund
1.10%
Individual Investor
1.06%
Venture Capital
0.77%
Pension Fund
0.61%
Bank and Trust
0.49%
機構持股
更新時間: 2月24日 週一
更新時間: 2月24日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
666
69.26M
107.27%
-1.65M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
2022Q4
635
64.56M
107.90%
-8.82M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
6.76M
10.58%
+90.23K
+1.35%
Dec 31, 2024
T. Rowe Price Associates, Inc.
5.62M
8.79%
+315.30K
+5.94%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.00M
7.82%
+13.26K
+0.27%
Dec 31, 2024
Avoro Capital Advisors LLC
1.19M
1.85%
+1.19M
--
Dec 31, 2024
Wellington Management Company, LLP
4.28M
6.7%
+316.75K
+7.99%
Dec 31, 2024
State Street Global Advisors (US)
2.50M
3.91%
-265.50K
-9.60%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.49M
2.33%
+9.91K
+0.67%
Dec 31, 2024
William Blair Investment Management, LLC
1.94M
3.04%
+269.90K
+16.12%
Dec 31, 2024
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
Invesco Biotechnology & Genome ETF
3.22%
Tema Oncology ETF
2.46%
SPDR S&P Biotech ETF
2.26%
Virtus LifeSci Biotech Products ETF
1.91%
Motley Fool Small-Cap Growth ETF
1.68%
Direxion Daily S&P Biotech Bull 3X Shares
1.48%
American Century Focused Dynamic Growth ETF
1.32%
Hypatia Women CEO ETF
0.95%
JPMorgan Fundamental Data Science Small Core ETF
0.93%
Invesco Nasdaq Biotechnology ETF
0.68%
查看更多
Invesco Biotechnology & Genome ETF
佔比3.22%
Tema Oncology ETF
佔比2.46%
SPDR S&P Biotech ETF
佔比2.26%
Virtus LifeSci Biotech Products ETF
佔比1.91%
Motley Fool Small-Cap Growth ETF
佔比1.68%
Direxion Daily S&P Biotech Bull 3X Shares
佔比1.48%
American Century Focused Dynamic Growth ETF
佔比1.32%
Hypatia Women CEO ETF
佔比0.95%
JPMorgan Fundamental Data Science Small Core ETF
佔比0.93%
Invesco Nasdaq Biotechnology ETF
佔比0.68%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
